首页> 外文期刊>The Open Medicinal Chemistry Journal >Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors
【24h】

Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors

机译:N4-磺酰胺基-琥珀酸,邻苯二甲酸,丙烯酸和苯甲酰乙酸衍生物作为潜在DPP IV抑制剂的设计,合成和生物学评价

获取原文
           

摘要

As incidence rate of type?II diabetes mellitus continues to rise, there is a growing need to identify novel therapeutic agents with improved efficacy and reduced side effects. Dipeptidyl peptidase IV (DPP IV) is a multifunctional protein involved in many physiological processes. It deactivates the natural hypoglycemic incretin hormone effect. Inhibition of this enzyme increases endogenous incretin level, incretin activity and should restore glucose homeostasis in type II diabetic patients making it an attractive target for the development of new antidiabetic drugs. One of the interesting reported anti- DPP IV hits is Gemifloxacin which is used as a lead compound for the development of new DPP IV inhibitors. In the current work, design and synthesis of a series of N4-sulfonamido-succinamic, phthalamic, acrylic and benzoyl acetic acid derivatives was carried out. The synthesized compounds were evaluated for their in vitro anti-DPP IV activity. Some of them have shown reasonable bioactivity, where the most active one 17 was found to have an IC50 of 33.5 μM.
机译:随着II型糖尿病的发病率持续上升,越来越需要鉴定具有改善的功效和减少的副作用的新型治疗剂。二肽基肽酶IV(DPP IV)是一种涉及许多生理过程的多功能蛋白质。它使天然降血糖降血糖素激素作用失活。抑制该酶可增加内源性肠降血糖素水平,肠降血糖素活性,并应恢复II型糖尿病患者的葡萄糖稳态,使其成为开发新的抗糖尿病药物的有吸引力的靶标。已报道的有趣的抗DPP IV药物之一是吉米沙星,它被用作开发新型DPP IV抑制剂的先导化合物。在当前的工作中,进行了一系列N4-磺酰胺基-琥珀酸,邻苯二甲酸,丙烯酸和苯甲酰乙酸衍生物的设计和合成。评价合成的化合物的体外抗DPP IV活性。其中一些已经显示出合理的生物活性,其中最活跃的一个17的IC50为33.5μM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号